Skip to main content
PharmGen Science, Inc. logo

PharmGen Science, Inc. — Investor Relations & Filings

Ticker · 004720 ISIN · KR7004720009 KO Manufacturing
Open in API
Filings indexed 296 across all filing types
Latest filing 2021-03-25 Declaration of Voting R…
Country KR South Korea
Listing KO 004720

About PharmGen Science, Inc.

http://www.pharmgenscience.com/en/

PharmGen Science, Inc. is a pharmaceutical company engaged in the research, development, production, and sale of medicaments. The company's portfolio encompasses a range of prescription (ETC) and over-the-counter (OTC) drugs, including analgesics, antibiotics, and anti-inflammatory agents. A key strategic focus for the company is the discovery and development of novel drugs for gastrointestinal (GI) disorders. PharmGen Science aims to provide integrated pharmaceutical solutions by leveraging its diverse infrastructure and global network.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of an Annual General Meeting (AGM) for '우리들제약' (Woori-dle Pharmaceutical). It details the outcomes of agenda items such as financial statement approval, board/auditor appointments, and remuneration limits. This falls under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it provides the official outcome of shareholder votes at a general meeting.
2021-03-25 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion, key financial data (assets, liabilities, profit/loss), and auditor information for the fiscal year ending 2020-12-31. While it contains financial data, it is a standardized regulatory disclosure form announcing the submission of the audit report rather than the full, multi-page audit report document itself. Therefore, it fits the 'Audit Report / Information' category as it provides the core audit results and opinion. FY 2020
2021-03-17 Korean
사업보고서 (2020.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Woori-dle Pharmaceutical Co., Ltd. (우리들제약 주식회사) for the fiscal year ending December 31, 2020. It includes the independent auditor's report from Samil PricewaterhouseCoopers, the audit opinion, key audit matters, and the full set of financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, and Statement of Cash Flows). Since it is a standalone audit report containing financial statements and audit opinions, it is classified as an Audit Report. FY 2020
2021-03-17 Korean
[기재정정]주주총회소집결의
AGM Information Classification · 98% confidence The document is a 'Notice of Convocation of General Meeting of Shareholders' (주주총회소집결의) and a subsequent amendment (정정신고) regarding the agenda items for the meeting. It details the date, location, and specific agenda items (such as financial statement approval, director/auditor appointments, and remuneration limits) for the upcoming Annual General Meeting. This falls under the category of Proxy Solicitation & Information Statement (PSI) as it provides shareholders with the necessary information to vote on meeting agenda items.
2021-03-17 Korean
[기재정정]주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Correction Report' (정정신고) regarding a 'Notice of General Meeting of Shareholders' (주주총회소집공고). It details amendments to the agenda items for the upcoming AGM, including the addition of financial statement approval reports. While it contains financial data, this is provided as part of the proxy/meeting materials to inform shareholders prior to the vote. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2021-03-17 Korean
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy) and is a correction filing (정정신고) for a previously submitted proxy solicitation document. It contains financial statements (balance sheets, income statements, etc.) as part of the information provided to shareholders for the upcoming Annual General Meeting (AGM). While it contains financial data, it is fundamentally a proxy solicitation document (PSI) used to request shareholder votes for the AGM.
2021-03-17 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.